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network size on the relative effectiveness and cost-effectiveness of
recommended pharmacological venous thromboembolic events
(VTEs) prophylaxis for adult patients undergoing elective total knee
replacement surgery in the United Kingdom. Methods: A stepwise
literature search speciﬁcally designed to identify indirect evidence
was conducted to extend the original clinical review from the latest
National Institute for Health and Care Excellence (NICE) VTE technol-
ogy appraisal. Different network sizes or network orders, based on the
successive searches, informed three network meta-analyses (NMAs),
which were compared with a replicated base case. The resulting
comparative estimates were inputted in an economic model to
investigate the effect of network size on cost-effectiveness probabil-
ities. Results: Searches increased the number of indirect comparisons
between VTE interventions, progressively widening the relevant net-
work of studies for NMA. Precision around mean relative treatmentee front matter Copyright & 2014, International S
r Inc.
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K.effects was increased as the network was extended from the base case
to ﬁrst-order NMA, but further extensions had limited effect. Cost-
effectiveness analysis results were largely insensitive to variation in
clinical inputs from the different NMA orders. Conclusions: No stand-
ard methodology is currently recommended by NICE to identify the
most relevant network of studies for NMA. Our study showed that
optimizing the identiﬁcation of studies for NMA can extend the
evidence base for analysis and reduce the uncertainty in relative
effectiveness estimates. Although in our example network extensions
did not affect the acceptability of available treatments in VTE preven-
tion based on cost-effectiveness results, it may in other applications.
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The quantitative synthesis of clinical data is a key and often
necessary step to the relative effectiveness assessment of med-
ical interventions both premarket and postmarket launch. Meta-
analysis is widely used to combine results from multiple clinical
studies and considered best practice by many regulatory and
health technology assessment bodies in Europe and worldwide
[1]. The potential advantages, as well as standard methodology
for conducting meta-analysis, are well established in the scien-
tiﬁc community with acknowledged guidelines by the Cochrane
Collaboration and the Centre for Reviews and Dissemination [2,3].
Recent statistical developments are extending this analytical
approach to networks of studies, synthesizing evidence from
both direct and indirect treatment comparisons [4–6].When no head-to-head trial is available, studies evaluating A
versus B and B versus C can be used to compare A and C indirectly
using network meta-analysis (NMA). Indirect comparisons must be
connected by at least one common comparator, that is, treatment
B. Additional intermediate links may be required to connect two
treatments of interest, thereby increasing the degree of “removal”
or “separation” between comparisons and decreasing the degree of
inﬂuence on the analysis [7]. A number of methodological concerns
have been raised when extending an evidence base to include
indirect comparisons within a network of studies such as how to
best identify indirect evidence. The ISPOR Task Force on Indirect
Treatment Comparisons Good Research Practices published guid-
ance on how to conduct NMA and recommended Hawkins et al.’s
iterative search strategy to identify indirect evidence [7,8].
Although this search methodology can maximize the NMAociety for Pharmacoeconomics and Outcomes Research (ISPOR).
ciences, University of Leicester, Adrian Building, University Road,
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 4 1 6 – 4 2 3 417network by efﬁciently identifying indirect evidence, authors warn
that if more than a few links separate treatments (e.g., A and C),
results may be unreliable. Additional links can provide useful
information but may also increase between-study heterogeneity,
uncertainty around estimates, and inconsistency between direct
and indirect comparisons [7–9]. We carried out a case study to
evaluate the effect of study identiﬁcation methods and network
size on indirect treatment comparisons for the prevention of
venous thromboembolic events (VTEs) after total knee replacement
(TKR) surgery.
The use of pharmacological, as well as mechanical, prophy-
laxis for VTE—deep vein thrombosis (DVT) and/or pulmonary
embolism—after elective orthopaedic surgery is common practice
in the United Kingdom. In 2010, the National Institute for Health
and Care Excellence (NICE) published a clinical guideline on
reducing the risk of VTE in patients admitted to hospital; at that
time, ﬁve drugs were recommended: dabigatran etexilate, fonda-
parinux sodium, low molecular weight heparins, rivaroxaban,
and unfractionated heparin for patients with renal failure [10].
Based on relative effectiveness estimates compared with these
existing medicines, apixaban was also recommended in 2012 by
NICE for use in adult patients scheduled for elective total hip or
knee replacement [11]. These drugs were evaluated over time in
single technology appraisals and all shown to be cost-effective for
their given indication [11–13].Objectives
We built on the latest NICE VTE technology appraisal TA245 for
apixaban [11] to reanalyze the relative effectiveness and cost-
effectiveness of recommended pharmacological VTE prophylaxis
for adult patients undergoing elective TKR surgery in the United
Kingdom using NMA. We sought to evaluate the effect of differ-
ent network sizes on decision making for VTE prevention.Methods
Literature Review
A stepwise systematic literature review was conducted in MED-
LINE, Medline-in-Process, OLD Medline, EMBASE, and the
Cochrane Library in October 2012 to identify relevant studies.
The searches were replicated using the reported search strategies
for the apixaban appraisal clinical review and adapted usingTable 1 – Breadth-ﬁrst search strategy.
Search
order
Search
iteration
Search comparators
1 i All ﬁrst-order comparators except
one
ii First-order comparator
previously omitted
2 iii All second-order comparators
except one
iv Second-order comparator
previously omitted
3 v All third-order comparators
except one
vi Third-order comparator
previously omitted
Note. Adapted from Table 1 of Hawkins et al. [7].Hawkins et al.’s [7] breadth-ﬁrst search methodology presented in
Table 1 [11,14,15].
Breadth-ﬁrst searching is based on graph theory; it is an
uninformed or “naive” search process that aims to exhaustively
search a sequence or a combination of sequences from a “root”
node on a graph to all “neighboring” nodes without considering a
ﬁnal limit until it is reached. A parallel can be drawn between
nodes on a graph to interventions on a network map and the
need to identify all common comparators within a network
without knowing the ﬁnal size or shape of the network. Hawkins
et al. [7] refer to search “orders” and associated search compara-
tors to describe each sequential step in the breadth-ﬁrst search.
Treatments directly compared with ﬁrst-order comparators fol-
lowing ﬁrst-order searches become second-order comparators,
and so on. The sequence of searches in Table 1 progressively
include ﬁrst-, second-, and third-order comparators, allowing us
to identify all trials contributing to a network of evidence, until
no further comparators are identiﬁed. From the set of identiﬁable
trials, all relevant indirect comparisons are also identiﬁed at any
given order.
In accordance with Hawkins et al. [7], searches were divided
further for each order. In Table 1, search orders are numbered 1
to 3 and searches within each order i to vi. For example, in the
ﬁrst-order searches, all but one ﬁrst-order comparator are
included in the search terms (cf. search (1i) in Table 1). The
omitted comparator is searched separately in a subsequent
search iteration to ensure that all trials including one or more
ﬁrst-order comparators are captured and all possible second-
order comparators identiﬁed (cf. search (1ii) in Table 1). Search
(1i) will identify all trials comparing more than one of the ﬁrst-
order treatments, thus identifying any direct head-to-head
evidence, albeit one of the treatments is not included in the
search syntax. If the objective is to capture only ﬁrst-order (i.e.
direct) comparisons, the subsequent search (1ii) of the omitted
comparator is not required. In this instance, dividing the search
into two steps has the potential to reduce the search burden if a
particular comparator is associated with a large number of hits.
Hawkins et al. [7] thus recommend omitting a widely used
comparator such as placebo or best supportive care; however,
this is arbitrary. If further search orders are conducted and
abstracts reviewed, search (1ii) is redundant and each order
comparators could be searched at once. First-order comparators
can be arbitrarily selected within or outside the original scope of
searches and include treatments not of interest for appraisal.
Moreover, study selection is intentionally broadened to include
all clinical trials evaluating a ﬁrst-order comparator without a
restriction on comparator criteria, allowing for treatments that
may not fall within the scope for appraisal, such as unlicensed
drugs, nonrelevant treatments for decision making, or nonphar-
macological interventions, to contribute to the network of
evidence.
Studies were selected at the abstract and publication level on
the basis of the indicated population for TKR and restricted to
prospective, phases II to IV randomized controlled trials. To
replicate the search conditions and provide comparable model
results to the original technology appraisal, abstracts were
further restricted by date to studies published before September
2011 and to English language. Date restrictions were included in
the search strategy and exclusion of non-English abstracts and
publications took place during the screening phase.
Network Meta-Analysis
Network sizes were based on the studies selected following each
search order, thereafter referred to as ﬁrst-, second-, and third-
network orders. The base case was deﬁned a priori in the
apixaban appraisal from three pivotal phase III clinical trials
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and rivaroxaban 10 mg/qd to enoxaparin 40 mg/qd, respectively
[16–18]. In accordance with the submitted apixaban economic
model [14], these interventions form the decision space for VTE
prevention after TKR and are routinely used in clinical practice in
the United Kingdom. A comparison with fondaparinux was not
considered relevant by manufacturers or the evidence review
group because of its low market share in the United Kingdom and
was therefore excluded from the analysis. The evidence network
used in the original technology appraisal is referred to as the base
case and shown in Figure 2A.
A Bayesian NMA was conducted for each network order for the
composite outcome of total VTE and all-cause death, as well as for
total DVT, and any bleeds. Multiple outcomes were analyzed for
economic modeling purposes and to curb potential outcome
reporting bias for the composite measure of all VTE/all-cause
death used in more recent trials as primary outcome measure
but not frequently calculated in older studies [16–18]. Fixed- and
random-effects NMA models adjusted for multiarm trials were
used in WinBUGS version 1.4.3 to estimate odds ratios (ORs), using
Ades et al.’s codes available online [19,20].
The ﬁrst 20,000 simulations were discarded as a burn-in and
achieved reasonable convergence according to visual inspection
of trace and history plots. Main analyses were based on a further
50,000 iterations to ensure robustness of results. Model ﬁt was
evaluated using the total residual deviance and the deviance
information criterion (DIC) for each network size [21]. Between-
study heterogeneity was compared using the standard deviation
(SD) across random-effects models [22]. Inconsistency was
assessed by plotting the residual deviances against the number
of intervention arms in each included study, and looking at the
proportion of mixed P values under 5% and 10% signiﬁcance
[23,24]. We expect that if there was no inconsistency, the residual
deviance would equal the number of arms in each trial because it
should be equal to 1 for each data point. Mixed P values provide
an approximation to cross-validation P values, which can be
calculated in a single model run. According to Welton et al. [25],
mixed P values calculated from the same data set should follow a
uniform distribution on the interval (0,1). We plotted the ordered
P values for each study and each network order against uniform
order statistics to evaluate inconsistency looking at unusually
small or large P values [25].Economic Model
A combined decision tree and Markov chain was built in Excel
to model the initial prophylaxis/90-day postsurgery phase and
the following 35-year time horizon, respectively. The economic
model was rebuilt using the input data provided in the apixaban
manufacturer submission and evidence review group report.
The modeling approach and assumptions were externally vali-
dated against the original model [14,15]. Figure A in the
Appendix in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2014.02.013 illustrates the two-phase model
diagram.
Treatment effect was demonstrated only during the ﬁrst 90
days of the clinical pathway. We applied the ORs for all VTE/all-
cause death and any bleeds from the NMA to adjust the baseline
risk and inform transition probabilities in the decision tree.
Baseline risks were taken from the Apixaban Dose Orally vs.
Anticoagulation with Enoxaparin-2 trial for enoxaparin 40 mg/qd
as in the original technology appraisal [16]. The parameterization
of the Markov model was identical for all treatments compared.
Uncertainty around parameters was expressed in distributions; a
probabilistic sensitivity analysis was performed using 1000 model
runs sampling from these distributions. ORs for all VTE/all-causedeath and any bleeds were sampled from 10,000 Markov chain
Monte-Carlo simulations extracted from WinBUGS. Quality-
adjusted life-years were used to estimate incremental cost-
effectiveness ratios (ICERs) compared with enoxaparin; the 2.5th
and 97.5th percentiles were also extracted to demonstrate the
variation in uncertainty around mean ICER estimates at each
given order.Results
Literature Review
We considered the list of comparators included in the original
apixaban submission search strategy as ﬁrst-order comparators.
More than 25 product names and drug classes of interest for VTE
prevention in both total hip and knee replacement were included
as ﬁrst-order comparators. Different dosages were considered as
individual treatments in the analysis. A full search strategy and
the complete list of comparators included in each search order
are included in the Appendix (cf. Table A1-3 and Table B) in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2014.02.013.
Fifty-three clinical trials met the inclusion criteria over the
three network orders. Figure 1 shows the study selection ﬂow
diagram broken down by search and network order. The numbers
of studies included and excluded for each search iteration are
also presented and totaled by network order. Figure B in the
Appendix in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2014.02.013 illustrates the network map represent-
ing all treatment comparisons identiﬁed by successive search
orders. The number of randomized controlled trials included in
the NMA was limited to focus solely on treatment comparisons
that would inform the relative effectiveness estimates for apix-
aban 2.5 mg/bd versus relevant comparators for decision making
(i.e., dabigatran etexilate 220 mg/qd, enoxaparin 40 mg/qd,
rivaroxaban 10 mg/qd). Graphically, these comparisons are
referred to as “closed loops” within the network of studies.
Focusing on these loops allowed us to reduce the size of the
evidence base and make data sets more manageable without
biasing results, because excluded studies did not contribute to
indirect comparisons relevant to the decision space. Figure 2
illustrates the network diagrams for each search order including
only the closed loops with the interventions of interest shaded in
gray, as well as the base-case Indirect Treatment Comparison
(ITC) network for reference. Asterisks in Figure 2 indicate that
multiple drug dosages were represented by one node; although
different dosages were considered as individual treatments in the
analyses, these were not illustrated in the networks for read-
ability. Note that we included interventions from three-arm trials
even if only one treatment comparison from the trial was of
interest, such as in Wang et al. [26] comparing placebo, fraxipar-
ine (nadroparin calcium) 0.2 to 0.4 ml/qd, and indomethacin 25
mg/bd. Lastly, not all studies reported the outcomes of interest
and were de facto excluded from the NMA. The ﬁnal numbers of
studies in each NMA order for TKR are included in Figure 1 and
presented in tabular format in the Appendix (cf. Table C) in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2014.02.013, including studies reporting separate results for total
hip and knee replacement in the same publication.
Network Meta-Analysis
Goodness-of-ﬁt statistics for the ﬁxed- and random-effects NMA
models are presented in Table 2. Fixed-effects models for all
network orders were used because they provided the best ﬁt to
the data according to the DIC. Forest plots in Figure 3 summarize
1st network order
3rd network order
1285 hits excluded
pop. n/a (179)
intervention n/a (50)
outcome n/a (98)
study design n/a (862)
non-English (84)
not found (12)
1,410 hits
125 studies included*
29 studies for TKR
11 for TKR/THR
1st search order
duplicates removed
2nd search order
duplicates removed
3 hits
0 studies included
3 hits excluded
study design n/a (3)
3rd search order
duplicates removed
236 hits
29 studies included*
8 studies for TKR
2 for TKR/THR
4th search order
duplicates removed
206 hits excluded
pop. n/a (50)
intervention n/a (30)
outcome n/a (19)
study design n/a (84)
non-English (17)
not found (6)
122 hits
0 studies included
122 hits excluded
pop. n/a (75)
intervention n/a (9)
outcome n/a (24)
study design n/a (9)
non-English (4)
not found (1)
70 hits
16 studies included*
2 studies for TKR
1 for TKR/THR
5th search order
duplicates removed
54 hits excluded
pop. n/a (15)
intervention n/a (6)
outcome n/a (4)
study design n/a (23)
non-English (6)
6th search order
duplicates removed
28 hits
1 study included*
0 studies for TKR
0 for TKR/THR
27 hits excluded
pop. n/a (16)
outcome n/a (4)
study design n/a (5)
non-English (2)
Number of studies forming 
‘closed’ loops
Number of studies included 
in all VTE/all-cause death 
analysis
Number of studies included 
in total DVT analysis
Number of studies included 
in any bleeds analysis
18
11
17
10
Total number of studies 
included for TKR, TKR/THR 40
Number of studies forming 
‘closed’ loops
Number of studies included 
in all VTE/all-cause death 
analysis
Number of studies included 
in total DVT analysis
Number of studies included 
in any bleeds analysis
25
13
22
14
Total number of studies 
included for TKR, TKR/THR 50
Number of studies forming 
‘closed’ loops
Number of studies included 
in all VTE/all-cause death 
analysis
Number of studies included 
in total DVT analysis
Number of studies included 
in any bleeds analysis
26
13
23
14
Total number of studies 
included for TKR, TKR/THR 53
2nd network order
Fig. 1 – Study selection ﬂow diagram. Asterisk indicates that the remainder of the included studies were THR only. DVT, deep
vein thrombosis; n/a, not applicable; pop., population; THR, total hip replacement; TKR, total knee replacement; VTE, venous
thromboembolic event.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 4 1 6 – 4 2 3 419the mean ORs and 95% credible intervals (CrI) for all VTE/all-
cause death, total DVT, and any bleeds obtained for the base case
and three network sizes. Given the number of studies included
(cf. Fig. 1), second- and third-order NMAs for all VTE/all-cause
death and any bleeds were the same and results in Figure 3 are
presented only for completeness. The growing evidence base
from the base case to ﬁrst-network order marginally increased
precision around the mean ORs for all outcomes. For example,
the all VTE/all-cause death mean OR for dabigatran versus
enoxaparin decreased from 0.95 (95% CrI 0.74–1.22) to 0.90 (0.73–
1.10) between the base-case and ﬁrst-order analysis; similarly,
the uncertainty in any bleeds mean OR for apixaban versus
enoxaparin was reduced from 0.78 (0.51–1.26) to 0.72 (0.55–0.97).
Apixaban and rivaroxaban were superior to enoxaparin for both
efﬁcacy outcomes; however, ORs for dabigatran versusenoxaparin were inconclusive. Results favored apixaban over
dabigatran for all VTE/all-cause death for all network orders,
with a mean OR of 0.65 (0.51–0.85) for ﬁrst- and second-order
analyses. The NMA also estimated that patients are less likely to
experience a VTE event/death with rivaroxaban than with apix-
aban at higher network orders, although the base-case ITC did
not support the statistical superiority of rivaroxaban and this was
not demonstrated for total DVT. Apixaban showed the most
favorable safety proﬁle versus enoxaparin and versus rivaroxa-
ban for ﬁrst- and second-order NMA.
Although the ﬁxed effects provided the best model ﬁt for all
outcomes and all network orders, we considered the random-
effects models to assess between-study heterogeneity and the
consistency of the evidence. Results for the random-effects
models are included in the Appendix (cf. Figure C) in
(C) 2nd network order of studies (D) 3rd network order of studies
(A)Decision-making (base case) network of studies (B) 1st network order of studies
Fig. 2 – Network of studies including only “closed loops” based on search orders. Asterisk indicates multiple dosages
included.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 4 1 6 – 4 2 3420Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2014.02.013 Overall, results were consistent across all network
orders for both ﬁxed- and random-effects models with little
variation between respective point estimates and CrI. The
between-study heterogeneity estimates and CrI were reducedTable 2 – Goodness-of-ﬁt statistics for ﬁxed- and random
Network order Fixed effects
DIC Total residual deviance
Total VTE/all-cause death
First-order 260.97 39.92
Second-order 303.14 44.23
Third-order NA NA
All DVT
First order 366.15 52.48
Second order 468.65 70.59
Third order 490.00 80.1
Any bleeds
First order 237.87 33.46
Second order 303.89 42.29
Third order NA NA
Crl, credible interval; DIC, deviance information criterion; DVT, deep vei
venous thromboembolic event.for all VTE/all-cause death from 0.156 (0.005–0.588) to 0.108
(0.004–0.379)
and from 0.115 (0.003–0.569) to 0.108 (0.004–0.350) for any bleeds
from ﬁrst- to second-order NMA. The SDs increased, but not
considerably, from 0.092 (0.002–0.307) to 0.112 (0.006–0.341) and-effects NMA models for all network orders.
Random effects
DIC Total residual deviance SDs (95% CrI)
262.27 39.33 0.156 (0.005– 0.588)
304.45 43.95 0.108 (0.004– 0.379)
NA NA NA
369.14 52.96 0.092 (0.002– 0.307)
471.05 69.45 0.112 (0.006–0.341)
492.11 77.98 0.138 (0.015–0.391)
239.46 34.12 0.115 (0.003–0.569)
305.36 42.86 0.108 (0.004–0.350)
NA NA NA
n thrombosis; NA, not available; NMA, network meta-analysis; VTE,
0 1 2
Odds ratios
All VTE/all-cause death
apixaban 2.5mg vs. 
enoxaparin 40mg
rivaroxaban 10mg vs. 
enoxaparin 40mg
dabigatran 220mg vs. 
enoxaparin 40mg
apixaban 2.5mg vs. 
rivaroxaban 10mg
apixaban 2.5mg vs. 
dabigatran 220mg
0 1 2
Odds ratios
Total DVT
0 1 2
Odds ratios
Any bleeds
base case          1 order         2 order          3 order
favours 1st txt favours 2nd txt
0.55 (0.44-0.69)
0.59 (0.49-0.72)
0.59 (0.48-0.71)
0.59 (0.48-0.71)
0.46 (0.34-0.60)
0.45 (0.35-0.56)
0.45 (0.35-0.56)
0.45 (0.35-0.56)
0.95 (0.74-1.22)
0.90 (0.73-1.10)
0.90 (0.73-1.10)
0.90 (0.73-1.10)
1.19 (0.84-1.76)
1.31 (1.01-1.75)
1.31 (1.00-1.76)
1.31 (1.00-1.76)
0.57 (0.41-0.81)
0.65 (0.51-0.85)
0.65 (0.51-0.85)
0.65 (0.51-0.85)
favours 1st txt favours 2nd txt
0.53 (0.42-0.67)
0.57 (0.47-0.69)
0.57 (0.46-0.68)
0.57 (0.46-0.68)
0.48 (0.35-0.64)
0.46 (0.36-0.57)
0.46 (0.36-0.57)
0.46 (0.36-0.57)
0.94 (0.74-1.19)
0.93 (0.77-1.12)
0.93 (0.77-1.12)
0.93 (0.77-1.12)
1.10 (0.77-1.62)
1.24 (0.95-1.65)
1.23 (0.94-1.64)
1.23 (0.94-1.63)
0.56 (0.41-0.79)
0.61 (0.48-0.78)
0.60 (0.47-0.78)
0.60 (0.48-0.77)
favours 1st txt favours 2nd txt
0.82 (0.62-1.07)
0.79 (0.62-1.00)
0.79 (0.62-1.00)
0.79 (0.62-1.00)
1.03 (0.70-1.47)
1.10 (0.81-1.44)
1.10 (0.82-1.44)
1.10 (0.82-1.44)
0.99 (0.74-1.31)
1.02 (0.76-1.33)
1.02 (0.76-1.33)
1.02 (0.76-1.33)
0.78 (0.51-1.26)
0.72 (0.55-0.97)
0.72 (0.54-0.96)
0.72 (0.54-0.96)
0.81 (0.56-1.23)
0.77 (0.54-1.13)
0.77 (0.54-1.13)
0.77 (0.54-1.13)
Fig. 3 – Odds ratios for all VTE/all-cause death, total DVT, and any bleeds from ﬁxed-effects NMA models. DVT, deep vein
thrombosis; NMA, network meta-analysis; VTE, venous thromboembolic event.
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total DVT networks. Spiegelhalter et al. [22] provide a possible
interpretation of the random-effects SD by describing a “range” of
ORs. This range is in fact the ratio of the 97.5% to the 2.5% point of
the distribution of ORs for any given relative treatment effect.
They state that SDs on the OR scale of 0.1 or 0.2 will only ever
correspond to a range of ORs of 1.48 or 2.19, respectively [22].
Therefore, the SDs reported in Table 2, all smaller than 0.2,
showed little evidence of between-study heterogeneity.
Investigatory plots of residual deviances against the number
of intervention arms for each trial, outcome, and network order,
as shown in Figure D in the Appendix in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2014.02.013, do not sug-
gest any inconsistencies between direct and indirect evidence
across all models. We also plotted the ordered mixed predicted P
values against uniform order statistics and found the evidence to
be consistent across the three outcomes and network orders
(cf. Figure E in the Appendix in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2014.02.013). Although the plotted
mixed P values appear to deviate from a uniform distribution, no
individual P value was signiﬁcant at 5% or, more appropriately, at
10% due to the estimates being conservative by nature [25].
Lastly, analysis of both efﬁcacy outcomes—that is, all VTE/all-
cause death and total DVT—showed little variation largely due to
the relatively low risks of pulmonary embolism (fatal and non-
fatal) and death among surgical patients, suggesting no outcome
reporting bias for composite measures in the VTE literature.Economic Model
Apixaban, dabigatran etexilate, and rivaroxaban were found to be
cost-effective versus enoxaparin for all network orders. These
results were in line with ﬁndings from NICE appraisals that
recommended these treatments on the basis of their dominance
over enoxaparin. Table 3 presents the probabilistic sensitivity
analysis means for total costs, total quality-adjusted life-years,
and ICERs for the base case and ﬁrst- and second-network orders.
As previously stated, second- and third-order NMA results for all
VTE/all-cause death and any bleeds were the same, because
these were the clinical inputs to our model, and comparative
effectiveness analysis results for the third-network order were
redundant and not included in Table 3.The mean ICERs for rivaroxaban, apixaban, and dabigatran
etexilate were negative across all models, suggesting that treat-
ments were on average both more effective and less costly than
enoxaparin. The cost-utility analysis results showed little varia-
tion in outcomes despite the growing evidence base for the NMA
parameterizing the economic model. Figure F in the Appendix in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2014.02.013 shows the cost-effectiveness planes based on the
probabilistic sensitivity analysis results. At face value, these plots
appear uninformative with regard to the effect of network size on
the economic evaluation of compared pharmacological treat-
ments for VTE. The percentages in Table 3, however, indicate a
reduction in the uncertainty for which treatment is most cost-
effective at a £20,000 willingness-to-pay threshold from the base
case to ﬁrst-network order, with rivaroxaban’s predicted percen-
tages increasing from 83.2% to 97.1% cost-effective. In addition,
although the dominance of dabigatran versus enoxaparin is
asserted by all network orders and the mean outcomes do not
reﬂect any signiﬁcant change, the 2.5th and 97.5th percentiles
presented show the widest uncertainty in the ICERs.Discussion
Using a breadth-ﬁrst search strategy speciﬁcally designed to
optimize the identiﬁcation of indirect evidence allowed us to
extend the network of relevant studies for analysis. Extensions of
the network maximized the number of indirect comparisons
between existing VTE interventions, and precision was increased
from the base case to ﬁrst-network order because additional
studies reduced the uncertainty around mean ORs for all VTE/all-
cause death, total DVT, and any bleeds. Estimates, however,
became more stable as fewer studies were included in the
evidence networks with each subsequent search order. Authors
believe that additional information provided by trials comparing
existing treatments to a lower dose of enoxaparin (30 mg/bd)
identiﬁed in ﬁrst-order searches contributed in large part to the
increased precision across all outcome estimates. Overall, results
from the NMA were consistent across network orders and
extending the networks did not increase heterogeneity or incon-
sistency between studies. The cost-utility analysis was insensi-
tive to NMA results; variation in the clinical input data according
Table 3 – Cost-effectiveness results of apixaban, dabigatranetexilate, and rivaroxaban vs. enoxaparin for the
base case, ﬁrst-order, and second-order networks.
Interventions Total
costs (£)
Total
QALYs
ICERs (£) 2.5th percentile
uncertainty (£)
97.5th percentile
uncertainty (£)
% cost-
effective at
20K
% cost-
effective at
30K
Base case (ITC)
Rivaroxaban 703 9.32  3,412 4,171 2,957 83.2 83.3
Apixaban 810 9.27 3,703 4,627 3,109 16.8 16.7
Dabigatran
etexilate
1,377 9.04  17,920 76,636 75,111 0 0
Enoxaparin
40 mg
1,746 9.02 0 0
First-network order
Rivaroxaban 688 9.34 3,387 4,044 2,956 97.1 97.1
Apixaban 860 9.26 3,851 4,807 3,225 2.9 2.9
Dabigatran
etexilate
1,275 9.09 7,907 48,454 25,412 0 0
Enoxaparin
40 mg
1,748 9.03 0 0
Second-network order
Rivaroxaban 695 9.33 3,380 4,043 2,920 96.3 96.3
Apixaban 868 9.25 3,841 4,771 3,181 3.7 3.7
Dabigatran
etexilate
1,293 9.08 8,197 55,296 47,541 0 0
Enoxaparin
40 mg
1,754 9.02 0 0
Note. Third-network orders for included model inputs are the same as second-network orders so model results not presented above.
ICER, incremental cost-effectiveness ratio; ITC, indirect treatment comparison; QALY, quality-adjusted life-year.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 4 1 6 – 4 2 3422to network order did not affect mean ICERs but reduced the
uncertainty in outcomes without inﬂuencing the acceptability of
interventions.
A number of limitations and methodological challenges
should be addressed. Authors did not ﬁnd an in-depth explora-
tion of heterogeneity and inconsistency (e.g., node-splitting)
across order NMAs was warranted given the results and therefore
it was not performed. The selection of ﬁrst-order comparators
was arbitrary because no clear deﬁnition of how to optimally
choose these search terms currently exists. Hawkins et al. start
the iterative searches in their practical example looking at all
currently licensed treatments for non–small cell lung cancer
across regulatory jurisdictions [9]; our ﬁrst-order search consid-
ered indicated pharmaceutical interventions for VTE prophylaxis
in the United Kingdom. Although the NICE scoping process can
provide some grounds for deﬁning ﬁrst-order comparators,
depending on the therapeutic area, these can include four
interventions, that is, for second-line stage III/IV non–small cell
lung cancer, or 30 in our case study. This should not make a
difference but could affect how many search iterations are
needed in the breadth-ﬁrst strategy. In our case study, no
particular gains were achieved from further dividing search
orders because the additional burden of including all compara-
tors, even placebo, rather than all but one comparator was
marginal. Ultimately, all relevant comparators will be identiﬁed
in the sequence of searches; however, the incremental value of
higher search and network orders for NMA should be weighed
against the associated additional search and computational
burden. For example, the authors found that initially splitting
each search order as recommended by Hawkins et al. to mini-
mize the search burden, that is, searching for “all except one”
comparators and subsequently searching the omitted compara-
tor separately, proved inefﬁcient. We agree with Hawkins et al. [7]
that such omission is redundant if the next search order is
conducted and abstracts reviewed, as was the case in ourexample. In practice, searches conducted as part of a clinical
evidence review could inform ﬁrst-network order searches, even
if distinct study selection criteria may be required, and this could
help alleviate the search burden.
Efforts to widen an evidence base for analysis are highly
dependent not only on the literature available but also what
outcomes are reported in trial publications. Across all networks,
between 3 and 13 studies were excluded from our analyses because
they did not report outcomes of interest. Recent work in multiple
outcomes analysis could help maximize the evidence base and
improve NMAmethods [27–29]. Moreover, König et al. [30] propose a
new method to characterize the ﬂow of evidence in an NMA using
linear coefﬁcients to interpret the “parallelism” and “indirectness”
of networks to gauge the risk of bias, heterogeneity, and incon-
sistency within an indirect treatment comparison. Such methodo-
logical extensions to understand an evidence base, including how
searching and identifying indirect evidence could be examined
quantitatively to optimize network shape and size, are desirable.
Our application of Hawkins et al. [7] search methods to
evaluate the cost-effectiveness of VTE prophylaxis suggests that
more exhaustive searches to identify indirect evidence can
provide valuable additional information for NMA. As we extend
the breadth of searches, we can draw on more treatment
comparisons to inform the network of studies for analysis.
However, we are also more likely to include small sample size
and older studies, which may contribute to greater between-
study heterogeneity and increase the potential for time bias.
Given the contradictory results found by Hawkins et al. in their
similar study evaluating relative effectiveness estimates for non–
small cell lung cancer treatments across multiple network sizes,
the effect of extending the network size on uncertainty remains
case-speciﬁc [9]. Taken together with our ﬁndings, however, this
highlights the case for examining a wider network of evidence
and in the absence of guidelines, we tentatively recommend
Hawkins et al.’s search strategy to both future researchers and
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 4 1 6 – 4 2 3 423reviewers. This awareness should prevent, or at least discourage,
“gaming” when undertaking and reporting NMAs. To ensure
transparency, health technology assessment bodies should con-
sider wider networks for clinical review and evidence synthesis,
as well as to justify the use of narrower networks for economic
modeling and decision making. A simulation study to evaluate
the effect of network sizes and shapes for NMA would provide
generalizable ﬁndings and help formalize guidance on the added
value of indirect searching and network extensions.
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